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Case report Sustained response of carcinoma ex pleomorphic 
adenoma treated with trastuzumab and 
capecitabine
Elad Sharon1, Ronan J Kelly1 and Eva Szabo*2
Abstract
Background: Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall 
poor prognosis. Limited histopathologic analyses have shown that some such tumors exhibit significant HER2/neu 
immunoreactivity, suggesting a potential role for HER2-based therapy. We report here a case of a 58-year old man with 
metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination 
therapy with trastuzumab and capecitabine.
Case presentation: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent 
surgery followed by adjuvant radiation therapy. Multiple metastases to bone were documented one year later. Since 
the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with 
trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET 
scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of 
disease control for over 2 years.
Conclusion: This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with 
targeted therapy with trastuzumab in combination with chemotherapy. In the absence of definitive clinical trials which 
are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for 
trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex 
pleomorphic adenoma.
Background
Malignant salivary tumors represent 3 to 5% of all malig-
nant head and neck tumors, with 2500 new cases diag-
nosed in the Unites States yearly [1]. Carcinoma ex
pleomorphic adenoma is a rare, highly malignant tumor,
accounting for 11.7% of salivary malignancies [2]. It usu-
ally develops from malignant transformation of a long-
standing pleomorphic adenoma. Five-year survival for all
stages of carcinoma ex pleomorphic adeonoma ranges
from 30-76%, decreasing markedly for stage IV meta-
static disease [2,3]. Only 27% of patients are alive one year
after diagnosis of recurrence or metastasis.
There is no current chemotherapeutic standard for
treatment of metastatic salivary carcinomas. Due to the
infrequency of these tumors, the literature consists pri-
marily of case reports and small phase II studies which
combine multiple histologic subtypes. Objective response
rates in the 14-30% range and rarely as high as 50% for
cisplatin-based combinations have been reported [4].
Carcinoma ex pleomorphic adenoma has not been stud-
ied as a separate entity, and insufficient data exist regard-
ing response to standard chemotherapy. This case shows
a sustained response in a patient who was treated with
trastuzumab and capecitabine.
Case Presentation
A 58 year-old man with a 44 pack-year history of smoking
initially presented with a 3 year history of a painless right
neck mass and new temperomandibular joint pain. Fol-
low-up two months later after treatment with muscle
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relaxants revealed persistent pain and a new right facial
nerve palsy. Physical exam revealed a 2 cm nontender
palpable mass proximal to the right temperomandibular
joint, while CT and FDG-PET also showed three enlarged
hypermetabolic lymph nodes. Fine needle aspiration
revealed poorly differentiated carcinoma. The patient
underwent right total parotidectomy with sacrifice of cra-
nial nerve VII. Tumor size was 2 cm, 4/18 lymph nodes
(levels 2, 4, and 5) were involved by tumor, and the final
pathologic diagnosis was carcinoma ex pleomorphic ade-
noma, high grade. The final stage was T1N2bM0. He
received 60 Gy of radiation to the right parotid bed and
involved lymph nodes. One year later, FDG-PET revealed
multiple areas of increased bony uptake and bone biopsy
confirmed disease recurrence (Figure 1a).
At the time of documented recurrence, immunohis-
tochemical analysis of the original parotid resection
revealed 3+ HER2/neu staining. Subsequent FISH analy-
sis (performed after the patient was already on therapy)
showed that the HER2/neu gene was not amplified. Given
the strong immunostaining for HER2/neu and the known
benefit of combining HER2-directed therapy with che-
motherapy in HER2-overexpressing breast carcinoma,
therapy was initiated with trastuzumab 6 mg/kg every 21
days and capecitabine 2000 mg/m2 days 1-14 of a 21 day
cycle [5]. Zoledronic acid 4 mg every 21 days was also ini-
tiated in view of the extensive bone involvement. The
patient subsequently noted disappearance of bone pain
and return to his baseline energy level. Repeat FDG-PET
scan after three cycles revealed interval disease resolu-
tion with only physiologic uptake reported (Figure 1b).
With continued treatment, clinical and radiological
responses were sustained for greater than two years and
were ongoing at the time of the last contact with the
patient.
Conclusions
Our case demonstrates the potential utility of using tar-
geted therapy in combination with standard chemother-
apy in HER2/neu-overexpressing carcinoma ex
pleomorphic adenoma. There is a lack of knowledge
regarding the role of targeted therapies in the treatment
of salivary gland cancers. Recent data indicate that HER2/
neu immunohistochemical expression is relatively com-
mon in carcinoma ex pleomorphic adenoma, occurring
in 30-46% of cases [6,7]. However, clinical trials of HER2/
neu targeted therapies in salivary carcinomas have been
disappointing. Haddad et al. reported one extended
response with trastuzumab in 14 patients with metastatic
salivary gland cancers with HER2/neu expression, none
of whom had carcinoma ex pleomorphic adenoma [8].
Similarly, a phase II trial of lapatinib in 62 patients with
multiple histologic salivary carcinoma types with EGFR
and HER2/neu expression also did not show any true
responses [9].
However, two recent case reports, in addition to our
patient, suggest that HER2/neu is a potential molecular
t a r g e t  f o r  a  s u b g r o u p  o f  p a t i e n t s  w i t h  s a l i v a r y  g l a n d
tumors and strong HER2/neu immunoreactivity. Nashed
et al. recently reported a durable complete response in a
patient with ductal carcinoma arising in a pleomorphic
adenoma who was treated with docetaxel and trastu-
zumab after initial stabilization with trastuzumab alone
[10]. This patient's tumor strongly expressed HER2/neu,
although FISH results were not reported. After initial dis-
ease stabilization with trastuzumab alone for five months,
tumor progression was noted. Addition of docetaxel led
to complete response of metastatic disease. A similar case
report by Prat et al. confirmed this approach in a patient
with metastatic salivary duct carcinoma who was suc-
cessfully treated with trastuzumab in combination with
carboplatin and taxol [11]. This patient's tumor, in con-
trast to our patient and the case described by Nashed and
colleagues, apparently did not arise within a pleomorphic
adenoma, but strongly expressed HER2/neu and was
FISH-positive. Of interest, our patient's tumor was not
FISH-positive despite being highly immunoreactive for
HER2/neu. Nevertheless, all three cases of highly
expressing HER2/neu salivary cancers show durable
responses when trastuzumab was combined with any of
three different chemotherapy regimens, suggesting that it
may not matter which cytotoxic agent is added to trastu-
zumab to achieve a response. Since carcinoma ex pleo-
morphic adenoma is a very rare tumor and HER2/neu
expressing salivary glad cancers of this (or another) sub-
type are relatively uncommon, it is unlikely that definitive
clinical trials will be conducted. In the absence of such
data, the case reported here, taken together with the two
other above described cases, suggests that HER2/neu
expression should be assessed in these salivary carcino-
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mas and HER2-targeted therapies may provide signifi-
cant clinical benefit in the appropriately selected patient
subgroup.
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